FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2924012904> ?p ?o ?g. }

• W2924012904 endingPage "86" @default.
• W2924012904 startingPage "82" @default.
• W2924012904 abstract "Perampanel (PER) is a new antiepileptic drug (AED) with a novel mechanism of action. Investigations of the efficacy and safety of PER in pediatric and adult patients have increased recently. Although the clinical usefulness and pharmacokinetics of PER have been investigated in adolescent and adult populations, similar studies have not been performed in children.We retrospectively reviewed the medical records of patients treated with PER for more than 6 months in the Department of Pediatrics, Hiroshima University Hospital, between September 2016 and November 2018. We obtained demographic and clinical data including age, sex, epilepsy type, seizure type, seizure frequency before and after treatment initiation, adverse events, reasons for discontinuing PER treatment, doses at evaluation points, serum concentrations, concomitant AEDs, intellectual status, and epilepsy etiology. Seizure types and epilepsy syndromes were classified according to the criteria of the International League Against Epilepsy.The study included 44 patients (22 males) between the ages of 6 months and 16 years. Of those, 10 patients discontinued PER therapy. The 50% response rate was 52.3% in patients treated with PER, and four patients achieved complete seizure control. Perampanel was highly effective in patients with generalized and focal epilepsy (50% responder rates, 52.9% and 50.0%, respectively). Favorable response rates were observed for tonic-clonic, focal nonmotor, and absence seizures with 50% response rates of 54.5%, 50.0%, and 66.7%, respectively. The 50% responder rate was 31.3 for epileptic spasms (ES). Treatment-emergent adverse events (TEAEs) included somnolence (n = 8), irritability (n = 2), ataxia (n = 2), and one case each of dizziness, compulsiveness, and enuresis. Serum concentrations of PER were compared in patients taking concomitant enzyme-inducing antiepileptic drugs (EIAEDs; carbamazepine, phenytoin, and phenobarbital) and those taking concomitant non-EIAEDs. Serum PER concentrations were correlated with dose per body weight in both groups (EIAED: r = 0.765, p = 0.00000212; non-EIAED: r = 0.71, p = 0.0000158). The mean concentration-to-dose (CD) ratio was 2398.4 ng mL-1 mg-1 kg-1 (range: 800-4524.7) in the non-EIAED group and 693.7 ng mL-1 mg-1 kg-1 (range: 344-1309.7) in the EIAED group. Serum PER levels were lower in the EIAED group than in the non-EIAED group. All patients with serum PER concentrations above 400 ng/mL experienced somnolence.Perampanel is effective against various types of seizures, including ES, in pediatric patients with refractory epilepsy. Furthermore, PER has good tolerability when the dose is adjusted based on serum concentrations. The PER CD ratio was lower in pediatric patients than in adolescents and adults; therefore, clinicians must consider the CD ratio when treating children with PER." @default.
• W2924012904 created "2019-04-01" @default.
• W2924012904 creator A5000658838 @default.
• W2924012904 creator A5027300481 @default.
• W2924012904 creator A5075638450 @default.
• W2924012904 creator A5076050531 @default.
• W2924012904 creator A5091450023 @default.
• W2924012904 date "2019-05-01" @default.
• W2924012904 modified "2023-10-14" @default.
• W2924012904 title "Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy" @default.
• W2924012904 cites W1551373999 @default.
• W2924012904 cites W1970988925 @default.
• W2924012904 cites W1978795921 @default.
• W2924012904 cites W2086635829 @default.
• W2924012904 cites W2135808877 @default.
• W2924012904 cites W2324286688 @default.
• W2924012904 cites W2327973078 @default.
• W2924012904 cites W2516670073 @default.
• W2924012904 cites W2560633658 @default.
• W2924012904 cites W2561337999 @default.
• W2924012904 cites W2592509339 @default.
• W2924012904 cites W2615944722 @default.
• W2924012904 cites W2748936142 @default.
• W2924012904 cites W2755222529 @default.
• W2924012904 cites W2778219252 @default.
• W2924012904 cites W2810385853 @default.
• W2924012904 doi "https://doi.org/10.1016/j.yebeh.2019.02.004" @default.
• W2924012904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30897534" @default.
• W2924012904 hasPublicationYear "2019" @default.
• W2924012904 type Work @default.
• W2924012904 sameAs 2924012904 @default.
• W2924012904 citedByCount "20" @default.
• W2924012904 countsByYear W29240129042019 @default.
• W2924012904 countsByYear W29240129042020 @default.
• W2924012904 countsByYear W29240129042021 @default.
• W2924012904 countsByYear W29240129042022 @default.
• W2924012904 countsByYear W29240129042023 @default.
• W2924012904 crossrefType "journal-article" @default.
• W2924012904 hasAuthorship W2924012904A5000658838 @default.
• W2924012904 hasAuthorship W2924012904A5027300481 @default.
• W2924012904 hasAuthorship W2924012904A5075638450 @default.
• W2924012904 hasAuthorship W2924012904A5076050531 @default.
• W2924012904 hasAuthorship W2924012904A5091450023 @default.
• W2924012904 hasConcept C118552586 @default.
• W2924012904 hasConcept C126322002 @default.
• W2924012904 hasConcept C137627325 @default.
• W2924012904 hasConcept C187212893 @default.
• W2924012904 hasConcept C197934379 @default.
• W2924012904 hasConcept C2778186239 @default.
• W2924012904 hasConcept C2778562196 @default.
• W2924012904 hasConcept C2779034229 @default.
• W2924012904 hasConcept C2779384505 @default.
• W2924012904 hasConcept C2779979230 @default.
• W2924012904 hasConcept C2780820931 @default.
• W2924012904 hasConcept C2780836401 @default.
• W2924012904 hasConcept C2780874087 @default.
• W2924012904 hasConcept C42219234 @default.
• W2924012904 hasConcept C71924100 @default.
• W2924012904 hasConceptScore W2924012904C118552586 @default.
• W2924012904 hasConceptScore W2924012904C126322002 @default.
• W2924012904 hasConceptScore W2924012904C137627325 @default.
• W2924012904 hasConceptScore W2924012904C187212893 @default.
• W2924012904 hasConceptScore W2924012904C197934379 @default.
• W2924012904 hasConceptScore W2924012904C2778186239 @default.
• W2924012904 hasConceptScore W2924012904C2778562196 @default.
• W2924012904 hasConceptScore W2924012904C2779034229 @default.
• W2924012904 hasConceptScore W2924012904C2779384505 @default.
• W2924012904 hasConceptScore W2924012904C2779979230 @default.
• W2924012904 hasConceptScore W2924012904C2780820931 @default.
• W2924012904 hasConceptScore W2924012904C2780836401 @default.
• W2924012904 hasConceptScore W2924012904C2780874087 @default.
• W2924012904 hasConceptScore W2924012904C42219234 @default.
• W2924012904 hasConceptScore W2924012904C71924100 @default.
• W2924012904 hasLocation W29240129041 @default.
• W2924012904 hasLocation W29240129042 @default.
• W2924012904 hasOpenAccess W2924012904 @default.
• W2924012904 hasPrimaryLocation W29240129041 @default.
• W2924012904 hasRelatedWork W1993609519 @default.
• W2924012904 hasRelatedWork W1993852409 @default.
• W2924012904 hasRelatedWork W2015861704 @default.
• W2924012904 hasRelatedWork W2583821718 @default.
• W2924012904 hasRelatedWork W2912177640 @default.
• W2924012904 hasRelatedWork W2912232363 @default.
• W2924012904 hasRelatedWork W3127736844 @default.
• W2924012904 hasRelatedWork W3132977057 @default.
• W2924012904 hasRelatedWork W4205388612 @default.
• W2924012904 hasRelatedWork W1468571555 @default.
• W2924012904 hasVolume "94" @default.
• W2924012904 isParatext "false" @default.
• W2924012904 isRetracted "false" @default.
• W2924012904 magId "2924012904" @default.
• W2924012904 workType "article" @default.